Department of Kinesiology and Health Education, 377659The University of Texas at Austin, Austin, TX, USA.
Department of Surgery and Periopertative Care, 377659The University of Texas at Austin, Austin, TX, USA.
Am Surg. 2022 Sep;88(9):2302-2308. doi: 10.1177/00031348221103657. Epub 2022 May 24.
The potential for prehabilitation programs to impact clinical outcomes is uncertain in abdominal cancer patients due to the short window of time to intervene and the weakened state of the patients. To improve the effectiveness of prehabilitation intervention, a multimodal sports science approach was implemented.
Prior to cancer-related surgery, 21 patients participated in a 4-week exercise and nutrition prehabilitation program comprised of blood flow restriction exercise (BFR) and a sports nutrition supplement. Retrospective data of 71 abdominal cancer patients who underwent usual preoperative care was used as a comparator control group (CON). At 90 days post-surgery, clinical outcomes were quantified.
Prehabilitation was associated with a shorter length of hospital stay ( = .02) with 5.5 fewer days (4.7 ± 2.1 vs 10.2 ± 1.2 days in CON) and decreased incidence of any complications ( = .03). Prehabilitation was not related to incidence of serious complications ( = .17) or readmission rate ( = .59). The prehabilitation group recorded 58% more steps on day 5 after surgery ( = .043).
A 4-week home-based prehabilitation program composed of BFR training and sports nutrition supplementation was effective in reducing postoperative complications and length of hospital stay in older patients with abdominal cancer.ClinicalTrials.gov Identifier: NCT04073381.
由于腹部癌症患者干预时间窗口短且患者身体虚弱，康复前计划对临床结果产生影响的可能性尚不确定。为了提高康复前干预的效果，采用了多模式运动科学方法。
在与癌症相关的手术前，21 名患者参加了为期 4 周的运动和营养康复前计划，包括血流限制运动（BFR）和运动营养补充。回顾性分析了 71 名接受常规术前护理的腹部癌症患者的数据作为对照组（CON）。术后 90 天，量化了临床结果。
康复前与较短的住院时间相关（ =.02），住院天数减少 5.5 天（4.7 ± 2.1 天 vs CON 组的 10.2 ± 1.2 天），任何并发症的发生率降低（ =.03）。康复前与严重并发症的发生率无关（ =.17）或再入院率无关（ =.59）。康复组术后第 5 天的步数增加了 58%（ =.043）。
为期 4 周的基于家庭的康复前计划，包括 BFR 训练和运动营养补充，在老年腹部癌症患者中有效降低了术后并发症和住院时间。
ClinicalTrials.gov 标识符：NCT04073381。
